David L Bushnell
Overview
Explore the profile of David L Bushnell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh S, Hope T, Bergsland E, Bodei L, Bushnell D, Chan J, et al.
J Natl Cancer Inst
. 2023 May;
115(9):1001-1010.
PMID: 37255328
Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although the treatment options...
2.
Love C, Desai N, Abraham T, Banks K, Bodei L, Boike T, et al.
Clin Nucl Med
. 2022 May;
47(6):503-511.
PMID: 35507433
Objectives: This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs)...
3.
Love C, Desai N, Abraham T, Banks K, Bodei L, Boike T, et al.
Am J Clin Oncol
. 2022 May;
45(6):233-242.
PMID: 35507413
Objectives: This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs)...
4.
Strosberg J, Srirajaskanthan R, El-Haddad G, Wolin E, Chasen B, Kulke M, et al.
J Nucl Med
. 2021 Mar;
PMID: 33771903
We report the impact of Lu DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors (NETs) often find burdensome. All patients enrolled in...
5.
Bushnell D, Bodeker K, ODorisio T, Madsen M, Menda Y, Graves S, et al.
J Nucl Med
. 2021 Jan;
62(9):1274-1277.
PMID: 33517327
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose remains challenging because of critical-organ dose limitations. Adding I-metaiodobenzylguanidine (I-MIBG) to...
6.
Bushnell D, Bodeker K
Surg Oncol Clin N Am
. 2020 Mar;
29(2):317-326.
PMID: 32151363
Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment of patients with metastatic neuroendocrine tumors, delivering modest objective tumor response rates but notable survival and symptomatic benefits. The...
7.
Hope T, Abbott A, Colucci K, Bushnell D, Gardner L, Graham W, et al.
J Nucl Med
. 2019 Jul;
60(7):937-943.
PMID: 31263080
With the recent approval of Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing. Representatives from the North American Neuroendocrine Tumor Society and the...
8.
Menda Y, Madsen M, ODorisio T, Sunderland J, Watkins G, Dillon J, et al.
J Nucl Med
. 2018 Mar;
59(11):1692-1698.
PMID: 29523629
Pretherapy PET with Y-DOTATOC is considered the ideal dosimetry protocol for Y-DOTATOC therapy; however, its cost, limited availability, and need for infusion of amino acids to mimic the therapy administration...
9.
Menda Y, ODorisio T, Howe J, Schultz M, Dillon J, Dick D, et al.
J Nucl Med
. 2017 Feb;
58(7):1054-1057.
PMID: 28153957
Localization of the site of the unknown primary tumor is critical for surgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases. Forty patients with metastatic NET and unknown...
10.
Bushnell D, Madsen M, Ocdorisio T, Menda Y, Muzahir S, Ryan R, et al.
EJNMMI Res
. 2015 Jun;
4(1):38.
PMID: 26116109
Background: Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient radiation dose to the tumor to result in...